Methodological analysis reveals the limits of average treatment effects in corporate decision-makers, highlighting the need for localized firm-specific models.
What explains the increasing disconnect between empirical strategy research and real-world strategy? Although empirical methods have evolved, notably in the use of techniques that support causal identification, we argue that empirical strategy’s focus on estimating well-identified average treatment effects from a population-level model of performance is fundamentally misaligned with the strategist’s need for firm-specific insights about how to build firm-specific models that guide strategic decision making. This misalignment poses a critical problem because strategic decisions are typically one-shot, nondiversifiable, and deeply interconnected with other firm-specific choices. Thus, strategists require localized, firm-specific models and estimates rather than population-level average treatment effects. Through an extended empirical example, this paper demonstrates the limits of strategy’s current approach of ever-more-precise identification and offers guidance about methodological approaches that can help bridge the relevance gap.
No takes yet. Share an insight, caveat, or question.
Snyder et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: